Drug Derivative Reversed MS Symptoms in Mouse Study
Researchers found that a modified antiviral agent repaired motor and vision function in animal models of multiple sclerosis.
Updated on Sept. 23, 2026 in Stroke
Live Poll
Do you trust that repurposing existing medications is an effective strategy for developing new disease treatments?
A study published on September 23, 2026, in Science Translational Medicine found that a non-toxic drug derivative, kamuvudine-9, reversed paralysis and vision loss in mice with multiple sclerosis. The researchers also identified a potential link between the use of similar antiviral medications and lower rates of the disease in human patients.
Why it matters
This development suggests a new therapeutic avenue for preventing nerve damage in autoimmune conditions by targeting the inflammasome in the brain and spinal cord. Understanding this mechanism could eventually change how clinicians approach neuroprotection and disease progression in multiple sclerosis.
In a study of 3 million patient records, researchers observed lower rates of multiple sclerosis diagnosis among those taking NRTIs for HIV or hepatitis B. Preclinical results showed that kamuvudine-9 reversed motor and vision deficits in mice over a two-week period.
The players
University of Virginia
A public research university where the study identifying the potential of kamuvudine-9 was conducted.
Science Translational Medicine
A peer-reviewed journal published by the American Association for the Advancement of Science that focuses on biomedical research.
The details
Kamuvudine-9 is a modified derivative of NRTIs stripped of antiviral properties to minimize potential toxicity. It functions by inhibiting the activation of the inflammasome, a protein complex that triggers inflammation in the brain and spinal cord. In animal models, the treatment protected axons and myelin sheaths from degeneration, leading to lower levels of the neurofilament light chain biomarker.
Timeline
September 23, 2026: The study was published in Science Translational Medicine.
Health Landscape
This research builds on existing clinical trials exploring kamuvudine-9 for conditions like thyroid eye disease and diabetic macular edema. By investigating its effects on the central nervous system, scientists are exploring how repurposing established drug scaffolds can address neurodegenerative autoimmunity.
While these findings are promising, they are currently limited to preclinical mouse models and large-scale observational claims data. Patients with multiple sclerosis should continue their current treatment plans and discuss any interest in clinical research updates with their neurologist.
The takeaway
Kamuvudine-9 effectively reversed motor and visual impairment in mice by shielding nerve pathways from inflammation. Readers should keep an eye on clinical trial announcements for this drug, as researchers aim to transition these findings into human studies for multiple sclerosis and ALS.
Further reading
For broader information on managing neuro-inflammatory conditions, visit our Stroke section.
More information
Learn more about eye and nerve health research at the National Eye Institute information portal.
Live Poll
Do you trust that repurposing existing medications is an effective strategy for developing new disease treatments?
